Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Has Consensus Target Price of $43.46

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) have received an average recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $44.62.

A number of brokerages recently commented on TNGX. Weiss Ratings raised Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. William Blair started coverage on Tango Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Wall Street Zen cut Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. HC Wainwright boosted their price objective on Tango Therapeutics from $66.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Guggenheim boosted their price objective on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th.

Insiders Place Their Bets

In other news, insider Adam Crystal sold 27,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the sale, the insider directly owned 115,743 shares of the company’s stock, valued at $2,832,231.21. This represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jessica Newcomb sold 8,200 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the transaction, the insider owned 59,121 shares in the company, valued at $1,431,910.62. This represents a 12.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 6.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently bought and sold shares of TNGX. Allworth Financial LP raised its position in shares of Tango Therapeutics by 100.9% in the second quarter. Allworth Financial LP now owns 1,131 shares of the company’s stock valued at $35,000 after purchasing an additional 568 shares during the period. Nykredit A S purchased a new position in Tango Therapeutics during the second quarter valued at approximately $26,000. SG Americas Securities LLC grew its stake in Tango Therapeutics by 10.2% during the first quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock valued at $507,000 after acquiring an additional 2,251 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Tango Therapeutics by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock valued at $10,237,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new stake in Tango Therapeutics during the 2nd quarter worth approximately $122,000. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics News Summary

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Vopimetostat combined with Revolution Medicines’ daraxonrasib produced an 82% objective response rate and an 88% nine-month progression-free survival rate in 22 evaluable patients with previously treated MTAP-deleted, RAS-mutant pancreatic cancer. Median PFS had not yet been reached, and the disease-control rate was 100%. Tango Phase 1/2 pancreatic cancer results
• Positive Sentiment: Tango plans to begin a global, randomized registrational Phase 3 trial in front-line MTAP-deleted pancreatic cancer during the first half of 2027, comparing the combination with standard chemotherapy. The company also plans to discuss a potential second-line approval pathway with regulators. Tango Phase 3 development plans
• Positive Sentiment: Stifel raised its price target on TNGX to $55, signaling continued analyst confidence in the company’s clinical opportunity. Unusually heavy call-option activity also reflected speculative bullish interest, although options volume does not guarantee sustained buying. Stifel raises Tango price target
• Neutral Sentiment: The results are based on a small, non-randomized early-stage study. Although the data compare favorably with historical pancreatic cancer outcomes, confirmation in a larger controlled trial will be necessary.
• Negative Sentiment: Tolerability remains a concern: 40% of dose-level-one patients experienced Grade 3 treatment-related adverse events and 20% required dose reductions. The higher dose produced dose-limiting toxicities, while a Phase 3 start in 2027 leaves a lengthy period before potential commercialization. These factors likely contributed to the negative market reaction to otherwise strong data. Tango stock reaction to pancreatic cancer data

Tango Therapeutics Stock Down 16.4%

NASDAQ TNGX opened at $23.34 on Friday. The business has a 50 day simple moving average of $23.79 and a 200 day simple moving average of $25.27. Tango Therapeutics has a one year low of $7.12 and a one year high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, equities analysts predict that Tango Therapeutics will post -1.41 EPS for the current year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.